First US product approval for Taiho Oncology
This article was originally published in Scrip
Executive Summary
The US FDA has approved Taiho Pharmaceuticals Co. Ltd.'s Lonsurf (trifluridine and tipiracil), formerly known as TAS-102, for the treatment of metastatic colorectal cancer (mCRC). It is the first approval for Taiho's US oncology division. Launch is expected within the next two weeks but Lonsurf's price has yet to be disclosed.
You may also be interested in...
Merck Joins KRAS Stampede In Deal With Otsuka Affiliates
Merck & Co. is paying $50m up front to combine preclinical KRAS-target cancer compound pipelines with Astex and Taiho, both affiliates of Japan’s Otsuka. The two biotechs could realize up to $2.5bn in earnouts under the collaboration.
VC Roundup: Caribou Completes $30m Non-IPO CRISPR Financing; $205m In Cash For Five Others
Gene editing is all the rage in biotechnology these days, but Caribou Biosciences Inc. has taken a different path than its CRISPR peers by diversifying beyond therapeutics to agriculture, industrial and applied research. The company also has taken a different financing path – recently closing a $30m Series B venture capital round instead of pursuing an initial public offering.
UK Reimbursement Decisions Focus Mostly On Cancer
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.